Enzymatic and genetic polymorphisms of paraoxonase- 1 in the Gabonese population: The relation to lipid parameters in patients with diabetes by Abessolo, FA et al.
Original Research: Enzyme and genetic polymorphisms of paraoxonase-1 in the Gabonese population
92 2012 Volume 17 No 2JEMDSA
Introduction
Cardiovascular disease is a major cause of morbidity 
and mortality in developed countries.1 In developing 
countries, particularly in Africa, there is an upsurge 
of metabolic diseases such as obesity, type 2 
diabetes and atherosclerosis, and its cardiovascular 
complications. All these entities partially share a 
common basis, namely the development of a state 
of imbalance between pro-oxidant and antioxidant2 
factors. Paraoxonase-1 is a member of the three-gene 
family, PON 1, PON 2 and PON 3. PON 1, the best 
studied, is a calcium-dependent esterase and can 
hydrolyse organophosphates.3 This enzyme circulates 
bound to the high-density lipoproteins (HDLs) and 
prevents oxidation of HDLs and low-density lipoproteins 
(LDLs). The gene coding for PON 1 has three major 
polymorphisms that account for the variation of the 
enzymatic activity. Two of them are located in the 
coding region; a Gln (Q) Arg(R) substitution at position 
192, and a Leu (L)/Met (M) substitution at position 55. 
Another important polymorphism is located in the 
promoter region, at position -107, called T(-107)C.4 It 
has been suggested that low-serum paraoxonase-1 
activities are characteristic of metabolic syndrome, 
and may influence the metabolic-syndrome-related 
risk of coronary artery disease.5 Thus, paraoxonase-1 
may slow the evolution of the early stages of 
atherosclerosis, and may participate in the reduction of 
cardiovascular risk through its activities, depending on 
genetic and environmental factors.6 These properties 
make paraoxonase-1 important in the assessment of 
cardiovascular risk.7 However, international standards 
only require the inclusion of quantitative changes 
of plasma lipoproteins in the primary or secondary 
prevention of this risk,8 regardless of the oxidation 
effect. This study focuses on the relationship between 
the enzymatic activities of paraoxonase-1 and the lipid 
parameters of cardiovascular risk, in order to highlight 
the importance of these oxidative phenomena on the 
cardiovascular risk in a black patient population.
Method
Population 
This prospective survey was conducted from 30 
October 2010 to 1 March  2011. The study was carried 
out in the biochemistry laboratory of the Faculty of 
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Background: The objective was to study the relationship between the paraoxonase-1 activity, genetic 
polymorphisms and lipid parameters in a black patient population.
Method: This study investigates patients with type 2 diabetes and hypertension for which concentrations of 
total high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides, apolipoprotein 
AI, apolipoprotein B100, the latency time of oxidation of small and dense LDL, arylesterase activity and genetic 
polymorphism of paraoxonase-1 at positions T(-107)C, L55M and Q192R were determined and compared to 
healthy subjects.
Results: Concerning the T(-107C) polymorphism, the -107T allele is higher in healthy subjects (0.325) than in those 
with diabetes (0.660). This was the same for the 55M allele, whereas the -107C allele was lower in  healthy patients 
(0.675) than in patients with diabetes (0.340). Paraoxonase-1 activity was lower in patients with diabetes than in 
healthy subjects, irrespective of genotype. The -107CC genotypes had higher HDL cholesterol AI apolipoprotein I 
concentrations than -107TT in the control group (p-value = 0.0001), patients with diabetes (p-value = 0.002), and 
patients with hyptertension (p-value = 0.001). This result was also obtained with the 55LL genotype. 
Conclusion: The prevalence of paraoxonase-1 alleles associated with lesser enzyme activities was found to be 
more common in patients with diabetes than in the control group. Possibly, this genetic distribution contributes to 
the high cardiovascular risk that is observed in certain black patients, compared to that in white patients.
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Medicine, in conjunction with the Department of 
Cardiology and Endocrinology of the Hospital Centre 
of Libreville, Gabon. Patients who consecutively 
consulted for diabetes and/or high blood pressure 
in these structures for the duration of this study were 
used as cases. Healthy subjects, free of disease, were 
recruited from the biochemistry laboratory of the 
Faculty of Medicine. Patients with type 1 diabetes, 
acute or chronic renal disease, who had had a stroke or 
coronary event in the last three months and who were 
taking lipid-lowering drugs, or estrogen or progesterone 
were excluded from the study, as were patients who 
had consumed alcohol the night before the sampling. 
This protocol took into account the ethical principles 
of research involving human subjects, enacted in the 
Declaration of Helsinki of 1964 and revised in 2004.9 All 
subjects signed the free informed consent forms, and 
the protocol was approved by the Gabonese national 
ethics committee. 
A questionnaire was administered to assess personal 
and family history, cardiovascular disease, smoking 
habits, diabetes and hypertension. Two blood pressure 
measurements were performed on each arm of the 
patient, after a rest of at least 15 minutes, using a usual 
sphygmomanometer. The two measurements were 
averaged. If the two readings differed (diastolic over 
15 mmHg systolic or more than 25 mmHg), a third 
reading was taken. The average of the two closest 
measurements was used subsequently. Patients in 
whom either the systolic or diastolic was equal to, or 
exceeded 140 and 90 mmHg respectively, or who were 
taking antihypertensive therapy, were considered to 
be hypertensive.10 Subjects whose fasting glucose was 
above 7 mmol/l and those taking hypoglycaemic 
drugs were considered to be patients with diabetes.11 
Samples were taken from patients who fasted 
for at least 10 hours, and were collected in tubes 
containing ethylene diamine tetraacetic acid (EDTA), 
as well as fluoride-oxalate tubes and plain tubes. After 
centrifugation at 3 000 revolutions per minute (rpm) 
for five minutes, plasma and sera were collected and 
stored at -70° C until assayed.
Conventional assays
The determination of total cholesterol and triglycerides 
was performed using standard enzymatic techniques 
based on samples taken in tubes containing EDTA. 
Glucose was assayed by the glucose oxidase method 
on the plasma obtained from samples taken in tubes 
containing potassium fluoride and sodium oxalate. 
LDL cholesterol was obtained by direct measurement 
from the serum, using a method based on the use 
of two detergents.12 HDL cholesterol was assayed 
by a method called Ultra Direct HDL Cholesterol, or 
Daïchi’s method, on a serum sample by selective 
detergent methodology accelerator.13  Apolipoprotein 
AI (ApoA1) and B100 (ApoB100) were measured by 
immunoprecipitation in the homogeneous phase with 
the reagent kit supplied by Orion Diagnostica® analyzer 
Mindray BS-200®. The intra- and interassay coefficients 
of variation were 2.7% and 4.4% for ApoAI, and 3.1% 
and 3.9% for ApoB100, respectively.
Extraction and oxidation of low-density lipoprotein 
and small dense low-density lipoprotein 
The precipitation reagent (0.1 ml) containing 150 U/ml 
of sodium heparin and 90 mmol/l MgCl2 was added to 
0.1 ml of a test serum, and the mixture was incubat-
ed at 37°C for 10 minutes. Samples were transferred 
to an ice bath for 15 minutes, then centrifuged at 
15 000 rpm for 15 minutes at 4°C. The clear supernatant 
contained the fraction of small dense low-density lipo-
protein.14  Thirty-two microlitres of CuCl2 (1 mmol/l) were 
added to 10 μl of this supernatant. The appearance of 
the reaction products of oxidation, conjugated dienes, 
was continuously registered at 37°C, using a spectro-
photometer at 234 nm.15
Assessing the arylesterase activity of paraoxonase-1
A volume of 0.1 ml of serum was added in a final 
volume of 250 μl containing 1 mmol/l of phenylacetate 
and 2 mmol/l of CaCl2 in Tris-HCl 20 mmol/l pH 
8.0. The initial rate of hydrolysis was determined 
spectrophotometrically at 270 nm.14
DNA extraction and genotyping
Deoxyribonucleic acid (DNA) was obtained from 
whole blood and extracted with phenol-chloroform.16 
Genotype determinations were carried out by an 
amplification reaction [polymerase chain reaction 
(PCR)] in an Eppendorf® thermocycler, followed by 
analysis of the fragments through enzymes restriction. 
Sixty pmol of oligonucleotide primers, KCl 62.5 μmol/l, 
MgCl2 15 mmol/l, 50 μmol/l of deoxynucleoside 
triphosphate, 1.5 U of Taq polymerase (Amersham 
Pharmacia Biotech) in buffer Tris-HCl 12.5 mmol/l and 
pH = 8.3 (all in a final volume of 50 µl), was added 
to 10 μg of DNA extract. T(-107)C polymorphism was 
determined by the method known as amplification 
refractory mutation system, a simple method for 
genotyping single nucleotide polymorphism.17 
Two first external sequences have been used, i.e: 
5’-GACGCAAGGACCGGATGGCACAAAGTGAGTG-3’ 
and TGGGCGCAGACACCGACGGGCTAGGAGGCTCT-3’ 
- and two first specific internal to two alleles of -107C (5’-attg-
TAGCTGCGGACCCGGCGGGGAGGAGC-3’) and 107T 
(5’-attgTAGCTGCGGACCCGGCGGGGAGGAGT-3’) 
to distinguish between T and C alleles at position -107. 
These internal primers contained a mismatch voluntary 
sequence, three bases upstream of the end 3’ (G → 
A) to minimise non-specific binding of primers 3’ which 
were non-complementary. A 5’(attg) sequence was 
also synthesised to prevent the reverse elongation 
(3’ → 5 ‘) chain. The amplification protocol was 
established on the basis of the mixture previously 
Original Research: Enzyme and genetic polymorphisms of paraoxonase-1 in the Gabonese population
94 2012 Volume 17 No 2JEMDSA
mentioned, a mixture to which dimethyl sulfoxide 
100 ml/l was added. External primers (30 pmol each) 
were added to each mixture’s reaction, followed 
by 30 amplification cycle, performed at 94°C for 30 
seconds, 64°C for 30 seconds, and 72°C for one minute, 
followed by a final extension at 72°C for six minutes. The 
PCR fragments were analysed on an agarose gel 2% 
with ethidium bromide staining and ultraviolet (UV) 
transillumination. For the PON 1 192 polymorphism, 
the PCR products were subjected to the action of the 
restriction enzyme AlwI for four hours at 37°C, then 
separated by electrophoresis on 3% agarose gel for 
75 minutes at 60 V with ethidium bromide staining 
and UV transillumination. PON 1 55 polymorphism was 
determined after the action of the restriction enzyme 
Hsp92II of the amplification products, followed by 
electrophoresis under the same conditions as before.
Statistical method
Continuous variables were expressed as mean and 
standard deviation, while qualitative variables were 
expressed as frequency. The comparison of quantitative 
variables was performed using the nonparametric 
Kruskal Wallis test. The chi-square Mantel-Haenszel was 
used to compare allele frequencies between groups. 
Two regression models were performed, namely a linear 
regression model including all the variables influencing 
PON 1 activity, and another regression carried out step 
by step, to select the most relevant variables based 
on their importance. The null hypothesis was rejected 
for p-values < 0.05. The statistical analysis of data was 
performed using Statistica 8® US Windows for StatSoft 
France.
Results
The epidemiological data of the studied cases are 
summarised in Table I. The study population was 
predominantly male (64.2%), with an average age of 
62.7 ± 12 years. Of the patients, 31.7% were patients 
with hypertension, 25.8% were patients with diabetes, 
15.8% were patients with diabetes and hyptertension, 
and 25.7% were considered to be healthy. 
In this entire cohort, genotyping at position -107 
showed a predominance of -107TC heterozygotes 
(0.440), followed by -107TT and -107CC homozygotes 
(Table II), corresponding to frequency of 0.540 for 
-107 T allele and 0.460 for -107C allele. At positions 
55 and 192, we obtained a predominance of 55LL 
genotypes (0.510) and 192RR (0.460), corresponding to 
frequencies of 0.695 and 0.635 for 55L and 192R alleles, 
against 0.365 and 0.305 for alleles 55M and 192Q, 
respectively. By contrast, in the control group, we 
obtained a prevalence of genotype -107CC (0.560) 
for a frequency of 0.675 for the -107C allele, and 0.325 
for -107T allele, respectively. In subjects with diabetes, 
the predominant genotype was -107TT, with an allele 
frequency of 0.660 and 0.695 -107T respectively, as they 
were simply diabetic or hypertensive and diabetic (vs. 
0.340 and 0.305 for allele C) at -107 position.
In the coding region at position 55, genotype 55LL 
was found in 66% of controls and 51% of patients with 
simple hypertension. This corresponded to the allele 
55L frequencies of 0.745 and 0.630 in controls and 
hypertensive subjects, respectively (vs. 0.255 and 0.370 
for allele 55M). However, in patients with diabetes, the 
frequency of the genotype 55LL dropped to 0.420 
and 0.340 in patients with diabetes and patients 
with diabetes and hypertension respectively, with 
frequencies of 0.470 and 0.420 for allele 55L in both 
groups, against 0.530 and 0.580 for allele 55 M.
The Q192R polymorphism was characterised by relative 
constancy in the distribution of alleles 192Q and 192R in 
the four identified groups. Indeed, the 192Q allele was 
found at a frequency of 0.290 in the control group and 
in subjects with hypertension. Its frequency was 0.244 
in subjects with diabetes and 0.230 in subjects with 
Table I: Epidemiological parameters of subjects setting numbers (%)








Age (years) 62.7 ± 12.0
Height (m) 1.62 ± 0.09
Body mass index (kg/m²) 27.4 ± 5.1
Male waist circumference 
(cm)
104 ± 12






Sport practice 320 (53.3)
Clinical category
Control group 160 (26.7)
Patients with diabetes 155 (25.8)
Patients with hypertension 190 (31.7)
Patients with hypertension 
and diabetes
95 (15.8)
Average weight (kg) 71.9 ± 9.7
Average systolic blood 
pressure (mmHg)
124 ± 6
Average diastolic blood 
pressure (mmHg)
81 ± 3
SD = standard deviation
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diabetes and hypertension (p-value = 0.432). Similarly, 
the 192R allele had a frequency of 0.710 in controls and 
subjects with hypertension. This frequency was 0.755 
in subjects with diabetes and 0.770 in subjects with 
diabetes and hypertension (p-value = 0.652).
The distribution of enzyme activities, based on clinical 
category and genotypes, is summarised in Table III. 
Genotypes associated with increased enzyme activity 
were -107CC and 55LL. However, the PON 1 activity 
was relatively constant, regardless of the polymorphism 
at position 192. On the other hand, a gradual decline 
of enzyme activity from the control group to that of 
patients with diabetes and hypertension, was noticed 
whatever the site of polymorphism concerned.
The relationship between polymorphisms whose 
genotypes had an effect on enzyme activities and 
lipid parameters is summarised in Tables IV and V. 
Among the parameters studied, and irrespective of the 
group of people, there was no association between 
LDL cholesterol concentrations and the different 
genotypes involved in the T(-107C) polymorphism. 
There was a relationship between the concentrations 
of HDL, ApoAI and the lag time and genotypes of the 
promoter region studied. This was regardless of patient 
category. A particular decrease in concentrations of 
HDL cholesterol and ApoAI in the same direction was 
observed, from the -107CC genotype to the -107TT, with 
heterozygotes CT occupying an intermediate position. 
Vertical analysis of Table IV showed the concentration 
of HDL cholesterol and a high lag period, homozygous 
-107CC in the control group. Both parameters 
decreased with the onset of the allele T. Regarding 
the L55M polymorphism, in the control group, 55LL 

















TT 0.21 0.19 (0.127) 0.57 (0.0001) 0.61 (0.001) 0.32
TC 0.23 0.21 (0.131) 0.18 (0.002) 0.17 (0.002) 0.44
CC 0.56 0.60 (0.231) 0.25 (0.0001) 0.22 (0.0001) 0.24
PON 1 55
LL 0.66 0.51 (0.01) 0.42 (0.0001) 0.34 (0.0001) 0.51
LM 0.17 0.24 (0.021) 0.10 (0.001) 0.16 (0.234) 0.37
MM 0.17 0.25 (0.001) 0.48 (0.0001) 0.50 (0.0001) 0.12
PON 1 192
QQ 0.16 0.21 (0.067) 0.11 (0.078) 0.11 (0.076) 0.19
QR 0.26 0.16 (0.052) 0.27 (0.467) 0.24 (0.413) 0.35
RR 0.48 0.53 (0.050) 0.62 (0.051) 0.65 (0.003) 0.46
p-values for comparison with the control group in brackets















PON 1 -107 (U/ml)
TT 65 ± 7 60 ± 5 (0.134) 50 ± 9 (0.043) 45 ± 12 (0.037) 56 ± 8
TC 79 ± 6 75 ± 6 (0.087) 60 ± 7 (0.047) 58 ± 6 (0.0001) 70 ± 7
CC 87 ± 8 81 ± 7 (0.057) 72 ± 13 (0.0021) 67 ± 12 (0.0001) 78 ± 10
PON 1 55 (U/ml)
LL 92 ± 7 81 ± 5 (0.046) 75 ± 4 (0.013) 64 ± 7 (0.0001) 80 ± 6
LM 76 ± 10 71 ± 10 (0.0634) 64 ± 9 (0.048) 55 ± 8 (0.0002) 68 ± 9
MM 65 ± 9 59 ± 7 (0.032) 52 ± 5 (0.0001) 47 ± 6 (0.0001) 57 ± 6
PON 1 192 (U/ml)
QQ 103 ± 17 81 ± 15 (0.0021) 71 ± 17 (0.0001) 58 ± 15 (0.0001) 81 ± 16
QR 95 ± 22 83 ± 11 (0.043) 75 ± 10 (0.0001) 63 ± 12 (0.0001) 81 ± 14
RR 98 ± 16 86 ± 12 (0.0235) 68 ± 18 (0.0001) 60 ± 10 (0.0001) 80 ± 14
p-values for comparison with the control group in brackets
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Table IV: Impact of genotype on lipid parameters according to -107CT polymorphisms
CC CT TT p-value
Control group
HDL cholesterol (mmol/l) 1.45 ± 0.04 1.24 ± 0.03 1.24 ± 0.04 0.0001
LDL cholesterol (mmol/l) 3.42 ± 0.04 3.40 ± 0.02 3.51 ± 0.04 0.851
ApoAI (g/l) 1.14 ± 0.03 1.00 ± 0.02 1.01 ± 0.03 0.005
Lag time (seconds) 90 ± 2 80 ± 5 75 ± 2 0.0001
Patients with diabetes
HDL cholesterol (mmol/l) 1.20 ± 0.01 0.91 ± 0.07 0.88 ± 0.06 0.002
LDL cholesterol (mmol/l) 4.25 ± 0.07 4.34 ± 0.05 4.42 ± 0.04 0.843
ApoAI (g/l) 0.92 ± 0.02 0.84 ± 0.03 0.82 ± 0.02 0.006
Lag time (seconds) 75 ± 4 60 ± 2 54 ± 4 0.0001
Patients with hypertension
HDL cholesterol (mmol/l) 1.40 ± 0.06 1.22 ± 0.04 1.20 ± 0.02 0.001
LDL cholesterol (mmol/l) 4.01 ± 0.04 3.95 ± 0.06 4.10 ± 0.05 0.765
ApoAI (g/l) 1.20 ± 0.02 0.95 ± 0.05 0.90 ± 0.04 0.001
Lag time (seconds) 80 ± 2 75 ± 4 70 ± 2 0.0001
Patients with  hypertension and diabetes
HDL cholesterol (mmol/l) 0.90 ± 0.02 0.75 ± 0.03 0.72 ± 0.04 0.002
LDL cholesterol (mmol/l) 4.63 ± 0.07 4.57 ± 0.06 4.62 ± 0.08 0.742
ApoAI (g/l) 0.84 ± 0.03 0.69 ± 0.02 0.70 ± 0.03 0.006
Lag time (seconds) 62 ± 4 53 ± 3 52 ± 4 0.0002
ApoA1: apolipoprotein AI, HDL: high-density lipoprotein, LDL: low-density lipoprotein
Table V: Impact of genotype on lipid parameters according to 55LM polymorphisms
LL LM MM p-value
Control group
HDL cholesterol (mmol/l) 1.64 ± 0.04 1.42 ± 0.05 1.13 ± 0.04 0.0001
LDL cholesterol (mmol/l) 3.47 ± 0.06 3.42 ± 0.05 3.38 ± 0.07 0.453
ApoAI (g/l) 1.32 ± 0.07 1.21 ± 0.06 1.10 ± 0.05 0.002
Lag time (seconds) 105 ± 5 95 ± 2 90 ± 4 0.0001
Patients with diabetes
HDL cholesterol (mmol/l) 0.74 ± 0.05 0.54 ± 0.04 0.58 ± 0.02 0.0001
LDL cholesterol (mmol/l) 4.45 ± 0.05 4.45 ± 0.07 4.43 ± 0.08 0.732
ApoAI (g/l) 1.11 ± 0.02 0.84 ± 0.08 0.78 ± 0.04 0.006
Lag time (seconds) 82.5 ± 5 70 ± 4 65 ± 5 0.001
Patients with hypertension
HDL cholesterol (mmol/l) 0.94 ± 0.06 0.82 ± 0.04 0.80 ± 0.03 0.002
LDL cholesterol (mmol/l) 4.32 ± 0.04 4.28 ± 0.06 4.31 ± 0.07 0.326
ApoAI (g/l) 0.85 ± 0.05 0.72 ± 0.03 0.69 ± 0.02 0.004
Lag time (seconds) 92 ± 4 83 ± 2 75 ± 2 0.001
Patients with  hypertension and diabetes
HDL cholesterol (mmol/l) 0.65 ± 0.05 0.49 ± 0.04 0.44 ± 0.02 0.004
LDL cholesterol (mmol/l) 4.19 ± 0.08 4.02 ± 0.05 4.20 ± 0.08 0.321
ApoAI (g/l) 0.92 ± 0.02 0.54 ± 0.03 0.51 ± 0.02 0.0001
Lag time (seconds) 72 ± 3 62 ± 2 57 ± 3 0.0001
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homozygotes had a higher concentration of HDL, of 
1.64 ± 0.04 mmol/l. This concentration decreased to 
1.13 ± 0.04 mmol/l in 55MM homozygotes. This decrease 
was observed in other patient groups, with a greater 
depletion of HDL in patients with hypertension and 
diabetes. Furthermore, the lag time of subjects in the 
control group and 55LL homozygotes, was 105 ± 5 
seconds against 90 ± 4 seconds in homozygous 55MM in 
the same group, with a significant difference (p-value = 
0.0001). The decrease of lag time with the appearance 
of the M allele was obtained with all groups of patients.
The results of the step-by-step regression analysis that 
was performed using all factors involved in the variability 
of PON 1 activity are shown in Table VI. The considered 
variables were those that were correlated with PON 1 
in multivariate analysis. The main dependent variables 
that determined the enzyme activity were ApoAI and 
lag time. The non-modifiable variables that had an 
influence on the arylesterase activity were age (r2 = 3.9, 
p-value < 0.00001), gender (r2 = 0.38, p-value < 0.006), 
genotype at position 55 (r2 = 3.0, p-value < 0.0001), and 
position -107 (r2 = 1.84, p-value < 0.0005), and body 
mass index (r2 = 0.55, p-value = 0.003).
Table VI: Step-by-step regression analysis of PON 1 determinants
Dependent parameters r2 p-value
Apolipoprotein AI 8.4 < 0.0001
HDL cholesterol 0.7 < 0.026
Lag time 9.1 < 0.0001
Age 3.0 < 0.0001
Genotype 55 2.7 < 0.0001
Genotype 107 1.7 < 0.0005
Triglycerides 0.60 0.035
Tobacco 0.59 0.038
Body mass index 0.55 0.003
Sport practice 0.43 0.005
Discussion
In this paper, we studied the relationship between the 
arylesterase activity of PON 1 and lipids parameters in 
a group of black patients with diabetes, compared 
to a control group. The enzyme activity used was 
arylesterase activity. Yet, the phenylacetate used as 
a substrate does not show a difference in reactivity 
with respect to the Q192R locus, as paraoxon. The only 
substrate that differentiates the activities of each of 
these alleles is paraoxon. The R192 isoform hydrolyses 
paraoxon nine times faster than the allozyme Q192.18 
Contrary to paraoxon, phenylacetate is easy to use 
and to obtain. Otherwise, the most commonly used 
method to measure the susceptibility of LDL to in-
vitro oxidation is the determination of the lag time of 
the formation of conjugated dienes, initiated by a 
catalytic amount of transition metals.15 The formation 
of conjugated diene represents an intermediate stage 
of the oxidation process. As an inverse relationship 
between the latency, the severity and the rate of the 
progression of coronary atherosclerosis, the lag time is 
considered to be the most discriminating index of the 
oxidisability of LDL.19
However, with this protocol, we showed that in subjects 
who were considered to be healthy, predominant 
genotypes in our population were -107CC and 192RR 
and 55LL. This distribution is similar to that found by 
Thyagarajan et al20 in the black patient population of 
the Coronary Artery Risk Development in Young Adults 
(CARDIA) study. The comparison of our distribution with 
that obtained in other populations is shown in Table VII. 
Distributions for 55L and 55M alleles were similar to those 
found in the United States and Brazil.21 Other distributions, 
especially for alleles 192Q and 192R, were different. 
Such a difference could be one of the factors involved 
in the conflicting results of epidemiological studies that 
have been conducted in different populations. If this 
hypothesis is true, then the incidence of diabetes and 
hypertension should be higher in Gabon, than in Korea 
or Thailand for example, other causes being equal. The 
association of PON 1 genotypes, enzymatic activity 
and parameters of oxidation suggests a particularly 
high cardiovascular risk in patients with diabetes in 
Gabon, compared to what could be expected in Asia. 
It is now suggested that the incidence of hypertension 
and cardiovascular mortality is higher in black patients 
Table VII: Comparison of the distribution of allele frequencies with that of other populations19
Population
(number of cases)
PON 1 55 PON 1 192
L M p-value Q R p-value
Gabon (120) 0.695 0.305 - 0.365 0.635 -
Korea (988) 0.941 0.058 0.007 0.705 0.295 < 0.0001
Thailand (475) 0.955 0.005 0.0001 0.710 0.290 < 0.0001
Iran (132) 0.590 0.410 0.032 0.690 0.310 < 0.0001
United States (2 553) 0.637 0.363 0.131 0.720 0.280 < 0.0001
Brazil (376) 0.640 0.360 0.131 0.660 0.340 < 0.0001
Italy (273) 0.601 0.399 0.061 0.711 0.289  < 0.0001
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living in urban zones than in Caucasians.22,23 Similarly, 
Hall et al have also shown a particularly significant 
increase of diabetes in African patients.24 However, the 
predominant genotypes in the control group also have 
the highest enzymatic activity outside the 192 position. 
These subjects are less likely to develop diabetes. The 
alleles -107T, 55M and 192R are prevalent in diabetics 
and are characterised by a low enzyme activity. The 
importance of these elements probably reflects the 
susceptibility of these individuals, whose PON1 activity 
results in a lower predisposition to developing diabetes, 
as suggested by the work of Martinelli.5 Therefore, the 
measurement of the PON 1 activity would provide 
supplemental information to the cardiovascular risk in 
this population. 
In the same way, Bhattacharyya et al25 have shown 
a decreased incidence of cardiovascular events 
in subjects whose PON 1 concentration is high. In 
addition, the decrease of PON 1 activity in patients 
with diabetes is followed by a decrease in HDL 
concentration. This result proves that it is rather the 
protective potential of atherogenesis that is defective 
in this particular situation. LDL is present, as we have 
demonstrated, but with a decrease in the HDL and PON 
1, a more intensive oxidative stress was obtained. This 
result is confirmed by Mastorikou et al26 who suggested 
that non-functional HDL in type 2 diabetes would 
be an additional factor in increased cardiovascular 
disease related to type 2 diabetes in metabolising 
20% less membrane hydroperoxides than the HDL of 
controls. This reduction in the antioxidant activity of 
HDL in diabetes may relate to the glycation of PON 
1 in these individuals and the oxidation of ApoAI and 
LDL. Genotypes and PON 1 activity are independently 
associated with concentrations of HDL and ApoAI. 
This relationship depends on the pathophysiological 
state. One interpretation of these data is that PON 1 
determines the concentration of HDL and ApoAI. The 
generally accepted hypothesis is that PON 1 was the 
main beneficiary in this association. Results showing 
the importance of HDL in the secretion and transport 
of PON 1, agreed with this.27 However, the relationship 
between the genotype and the HDL could also reflect 
an impact of PON 1 on the HDL, and is consistent 
with the independent associations of genotypes and 
enzyme activity in multivariate analyses. Indeed, the 
oxidation of ApoAI that can inhibit PON 120 disrupts the 
ability of the HDL to achieve cholesterol efflux from cells. 
This result was confirmed by Yildiz et al,28 who showed 
that hypertension was accompanied by an increase 
in the concentration of lipid hydroperoxides, total 
antioxidant status, and decreased enzymatic activity 
of arylesterase. Gaillard et al29 also demonstrated 
that the nature of the HDL in subjects who did not 
have diabetes could be responsible for increased 
cardiovascular events in the black patient population, 
despite a higher concentration of HDL. Our study 
relates paraoxonase activity to the polymorphism of its 
gene and to lipid concentrations in different groups of 
study.
We have demonstrated a consistently decreasing lag 
time from the control group to patients with diabetes 
and hypertension, regardless of the genotype in 
question, and this diminution related to the PON 1 
activity. This result corresponds with that of Nishtha 
et al.14 In fact, the oxidation of LDL cholesterol in an 
endothelial area that PON 1 can inhibit is considered 
to be as an important step in the development of 
atherosclerosis.30 
Smoking is among the parameters that may influence 
PON 1 activity. This result confirms other work from James 
et al31 that has shown that increased oxidative stress is 
one mechanism by which smoking exerts its deleterious 
influence on cardiovascular risk, although Sepahvand 
et al32 found that smoking did not have an influence on 
paraoxonase activity. But this author has worked with 
an Iranian population where smoking habits altered 
the results. Finally, we have found a decrease in PON 
1 activity with aging. This result is consistent with that 
found by other authors.33 The relationship between 
PON 1 activity and oxidative stress could take place 
according to a reduction-of-oxygen mechanism 
involving cysteine residues of PON 1 for example, 
because a reduction in PON 1 activity under oxidative 
stress conditions has been demonstrated.33 In this case, 
the system of regeneration of the reduced form of the 
enzyme still needs to be determined. 
Relations obtained between the genotype of PON 
1, PON 1 enzyme activity and other cardiovascular 
risk factors suggest that the Gabonese population 
is at particularly high cardiovascular risk. However, 
it seems necessary to search the haplotype with the 
higher enzymatic activity, and link this haplotype with 
the incidence of cardiovascular complications and 
diabetes in this population before the PON 1 activity is 
included in the assessment of cardiovascular risk.
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